Pyrazolyl-substituted heteroaryls and their use as medicaments

US10155751B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Matthias Hoffmann · Mittelbiberach, DE
• Georg Dahmann · Biberach an der Riß, DE
• Christian Gnamm · Biberach an der Riß, DE
• Daniel Robert Fandrick · Danbury, US
• John Scott · Abingdon, GB
• Clive McCarthy · Woodstock, GB

Key dates

• Filing date: Nov 10, 2017
• Grant date: Dec 18, 2018
• Expiry date: Nov 10, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to new substituted heteroaryls of formula 1 or of formula 1′ wherein A is either N or CH, wherein R2 is selected from the group consisting of —C1-3-alkyl, —C1-3-haloalkyl, F, Br, Cl, wherein Y is selected from —O— or —CH2—, and wherein R3 is defined as in claim 1, and the pharmaceutically acceptable salts thereof, and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.